Get the Stockscreener App
0.581
0.50%
-0.0029
Pre-market:
.56
-0.021
-3.61%
Evogene Ltd stock is traded at $0.581, with a volume of 152.98K.
It is down -0.50% in the last 24 hours and down -20.68% over the past month.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
See More
Previous Close:
$0.5839
Open:
$0.572
24h Volume:
152.98K
Relative Volume:
0.30
Market Cap:
$7.03M
Revenue:
$1.84M
Net Income/Loss:
$-17.51M
P/E Ratio:
-0.4195
EPS:
-1.3849
Net Cash Flow:
$-17.30M
1W Performance:
-0.34%
1M Performance:
-20.68%
6M Performance:
-44.43%
1Y Performance:
-57.90%
1-Day Range:
$0.55
$0.5893
1-Week Range:
$0.55
$0.618
52-Week Range:
$0.5206
$1.63
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.581 | 7.03M | 1.84M | -17.51M | -17.30M | -1.3849 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-21 | Initiated | ROTH Capital | Buy |
| Jul-29-21 | Initiated | Aegis Capital | Buy |
| Dec-01-20 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-16-13 | Initiated | Oppenheimer | Outperform |
Evogene Ltd Stock (EVGN) Latest News
Biomica CEO Set to Attend JP Morgan Healthcare Week in San Franc - GuruFocus
Evogene Shares Slip 2.6% as Biotech Stock Tests Key Support Level (EVGN)Wave Extension - newsline.com
Evogene Sets Up $2.9 Million At-the-Market Share Offering With A.G.P. - The Globe and Mail
Evogene enters sales agreement for at-the-market offering of up to $2.93 million - Investing.com Australia
Evogene Ltd. (NASDAQ: EVGN) launches $2.93M ATM program with A.G.P. - Stock Titan
Evogene (EVGN) launches $2.93M at-the-market share offering with A.G.P. - Stock Titan
EVGN Q1 2026 Earnings: Significant EPS Miss Amid Ongoing Operational ChallengesBasic EPS Analysis - newsline.com
Evogene Q1 revenue falls to $0.3 million amid strategic shift - scanx.trade
Full Transcript: Evogene Q1 2026 Earnings Call - Benzinga
Inside Evogene’s AI drug hunt: ChemPass platform hits BIO 2026 stage - Stock Titan
Earnings Call Summary | Evogene(EVGN.US) Q1 2026 Earnings Conference - 富途牛牛
EVGN Stock Price, Quote & Chart | EVOGENE LTD (NASDAQ:EVGN) - ChartMill
Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits
EVGN Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock DeclinesProfit Guidance Range - newsline.com
Evogene completes phase 1 trial of BMC128 cancer treatment By Investing.com - Investing.com South Africa
Evogene: Q1 Earnings Snapshot - AOL.com
Evogene (EVGN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Evogene says Phase 1 clinical study of BMC128 met primary endpoint - TipRanks
Evogene completes phase 1 trial of BMC128 cancer treatment - Investing.com
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica - PR Newswire
Evogene Ltd stock (IL0010831684): Shares trade quietly as investors await next catalysts - AD HOC NEWS
Evogene (EVGN) Edges Lower, Testing Key Support at $0.66Dealer Delta - newsline.com
Evogene Ltd (EVGN) Holding Near Support After Modest DeclineFibonacci Arc - The Legal Advocate
EVGN Q1 2026 Earnings: Significant EPS Miss Highlights Operational ChallengesShare Repurchase Impact - The Legal Advocate
Evogene Back Under $1 as Nasdaq Deadline Approaches - Bez Kabli
Evogene (EVGN) Edges Higher: Modest Uptick Amid Support Level TestFactor Crowding - The Legal Advocate
Evogene Ltd (EVGN) Q1 2026 Earnings Call Highlights: Strategic Collaborations Amid Financial ... By GuruFocus - Investing.com Canada
EVGN - Finviz
Evogene (EVGN) Slides 3% as Shares Test Key Support Near $0.66Put Wall - newsline.com
A. G. P. Maintains Evogene(EVGN.US) With Buy Rating, Cuts Target Price to $2.15 - Moomoo
Evogene shares decline after revenue miss despite stronger-than-expected earnings (EVGN) - MSN
Evogene Q1 2026 earnings preview - MSN
Evogene Ltd. (NASDAQ:EVGN) Q1 2026 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Evogene reports Q1 2026 loss, stock rises 1.95% By Investing.com - Investing.com South Africa
Evogene Earnings Call: AI Momentum vs. Cash Strain - The Globe and Mail
Evogene Reports First Quarter 2026 Financial Results - Global Agriculture
Evogene Ltd stock (IL0010831684): Q1 revenue slump highlights high?risk transformation phase - AD HOC NEWS
Evogene stock falls 5% on revenue miss despite earnings beat - Investing.com
Evogene earnings beat by $0.26, revenue fell short of estimates - Investing.com Australia
Evogene Q1 2026 Loss Deepens: -$0.60/Share vs -$0.28 Expected - AlphaStreet
EVGN: Revenue fell sharply and net loss widened as focus shifted to core AI-driven pharma and ag chem - TradingView
EVGN: AI-driven pharma and ag chemical focus advances, but Q1 revenue drops and net loss widens - TradingView
Earnings call transcript: Evogene reports Q1 2026 loss, stock rises 1.95% - Investing.com Canada
Evogene Ltd. Q1 2026 Earnings Call Summary - Yahoo Finance
Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Evogene reports Q1 results: net loss widens amid revenue decline - grafa.com
Evogene Shares Decline After Revenue Miss Despite Stronger-Than-Expected Earnings (EVGN) - Yahoo Finance
Evogene Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
Evogene Ltd files for offering of 2.45 million ordinary shares by selling shareholder SEC filing - marketscreener.com
Evogene 1Q Loss/Shr 60c >EVGN.TV - Moomoo
Evogene Ltd Files For Offering Of 2.45 Million Ordinary Shares By Selling Shareholder SEC Filing - TradingView
Evogene Ltd Stock (EVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):